These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

40 related articles for article (PubMed ID: 8509234)

  • 1. Pharmacokinetics and safety of single oral doses of amlodipine in patients with and without hepatic impairment: an open study.
    Darnis F; Poupon R
    Int J Clin Pharmacol Res; 1993; 13(1):29-33. PubMed ID: 8509234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single dose pharmacokinetics of manidipine in hepatic impaired patients and healthy controls.
    Deroubaix X; Lins RL; Lens S; Allemon A; Jeanbaptiste B; Poli G; Acerbi D; Stockis A; Ventura P
    Int J Clin Pharmacol Ther; 1998 Jul; 36(7):386-91. PubMed ID: 9707354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of moderate hepatic insufficiency on the pharmacokinetics of sitagliptin.
    Migoya EM; Stevens CH; Bergman AJ; Luo WL; Lasseter KC; Dilzer SC; Davies MJ; Wagner JA; Herman GA
    Can J Clin Pharmacol; 2009; 16(1):e165-70. PubMed ID: 19221403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vildagliptin, a novel dipeptidyl peptidase IV inhibitor, has no pharmacokinetic interactions with the antihypertensive agents amlodipine, valsartan, and ramipril in healthy subjects.
    He YL; Ligueros-Saylan M; Sunkara G; Sabo R; Zhao C; Wang Y; Campestrini J; Pommier F; Dole K; Marion A; Dole WP; Howard D
    J Clin Pharmacol; 2008 Jan; 48(1):85-95. PubMed ID: 17986525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of ciprofloxacin in impaired liver function.
    Esposito S; Miniero M; Barba D; Sagnelli E
    Int J Clin Pharmacol Res; 1989; 9(1):37-41. PubMed ID: 2707924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Results of a phase III, 8-week, multicenter, prospective, randomized, double-blind, parallel-group clinical trial to assess the effects of amlodipine camsylate versus amlodipine besylate in Korean adults with mild to moderate hypertension.
    Kim SH; Kim YD; Lim DS; Yoon MH; Ahn YK; On YK; Lee JW; Kim IJ; Park JB; Kim JJ; Chung WS; Yang JY; Seo HS; Shin EK; Kim HS;
    Clin Ther; 2007 Sep; 29(9):1924-36. PubMed ID: 18035192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amlodipine: pharmacokinetic profile of a low-clearance calcium antagonist.
    Abernethy DR
    J Cardiovasc Pharmacol; 1991; 17 Suppl 1():S4-7. PubMed ID: 16296697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of nilvadipine and amlodipine in patients with mild to moderate essential hypertension: a double blind, prospective, randomised clinical trial.
    Leonetti G;
    Curr Med Res Opin; 2005 Jun; 21(6):951-8. PubMed ID: 15969895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of hepatic impairment on everolimus pharmacokinetics: implications for dose adjustment.
    Kovarik JM; Sabia HD; Figueiredo J; Zimmermann H; Reynolds C; Dilzer SC; Lasseter K; Rordorf C
    Clin Pharmacol Ther; 2001 Nov; 70(5):425-30. PubMed ID: 11719728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Results of a multicenter, 8-week, parallel-group, randomized,double-blind, double-dummy, Phase III clinical trial to evaluate the efficacy and tolerability of amlodipine maleate versus amlodipine besylate in Korean patients with mild to moderate hypertension.
    Park S; Chung N; Kwon J; Yoon JH; Kim YJ; Han DS; Kim HS
    Clin Ther; 2005 Apr; 27(4):441-50. PubMed ID: 15922817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics, safety, and tolerability of the oral Renin inhibitor aliskiren in patients with hepatic impairment.
    Vaidyanathan S; Warren V; Yeh C; Bizot MN; Dieterich HA; Dole WP
    J Clin Pharmacol; 2007 Feb; 47(2):192-200. PubMed ID: 17244770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension.
    Philipp T; Smith TR; Glazer R; Wernsing M; Yen J; Jin J; Schneider H; Pospiech R
    Clin Ther; 2007 Apr; 29(4):563-80. PubMed ID: 17617280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of intravenous levosimendan and its metabolites in subjects with hepatic impairment.
    Puttonen J; Kantele S; Ruck A; Ramela M; Häkkinen S; Kivikko M; Pentikäinen PJ
    J Clin Pharmacol; 2008 Apr; 48(4):445-54. PubMed ID: 18303124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
    Ruilope LM; Malacco E; Khder Y; Kandra A; Bönner G; Heintz D
    Clin Ther; 2005 May; 27(5):578-87. PubMed ID: 15978306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic and pharmacodynamic assessments of the dipeptidyl peptidase-4 inhibitor PHX1149: double-blind, placebo-controlled, single- and multiple-dose studies in healthy subjects.
    O'Farrell AM; van Vliet A; Abou Farha K; Cherrington JM; Campbell DA; Li X; Hanway D; Li J; Guler HP
    Clin Ther; 2007 Aug; 29(8):1692-705. PubMed ID: 17919550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of dalbavancin in patients with renal or hepatic impairment.
    Marbury T; Dowell JA; Seltzer E; Buckwalter M
    J Clin Pharmacol; 2009 Apr; 49(4):465-76. PubMed ID: 19318696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of a therapeutic interchange from high-dose calcium channel blockers to a fixed-dose combination of amlodipine/benazepril in patients with moderate-to-severe hypertension.
    Hilleman DE; Reyes AP; Wurdeman RL; Faulkner M
    J Hum Hypertens; 2001 Aug; 15(8):559-65. PubMed ID: 11494095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The absolute bioavailability and pharmacokinetics of butorphanol nasal spray in patients with hepatic impairment.
    Vachharajani NN; Shyu WC; Garnett WR; Morgenthien EA; Barbhaiya RH
    Clin Pharmacol Ther; 1996 Sep; 60(3):283-94. PubMed ID: 8841151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical aspects of amlodipine pharmacokinetics].
    Kozyrev VN
    Ter Arkh; 1993; 65(9):75-80. PubMed ID: 8303605
    [No Abstract]   [Full Text] [Related]  

  • 20. [Clinical pharmacology of amlodipine].
    Gumułka W; Rewerski W
    Pol Tyg Lek; 1993 Dec 13-27; 48(50-52):820-4. PubMed ID: 7971499
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.